<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250228064873N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-02</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of upadacitinib versus methotrexate in morphea</public_title>
      <acronym>BAMDAD</acronym>
      <scientific_title>Evaluating the efficacy and safety of upadacitinib in the treatment of morphea compared to methotrexate in a randomized clinical trial in patients referred to the Morphea Clinic of Razi Hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93603</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be randomly allocated in a 1:1 ratio to either the upadacitinib group or the methotrexate group using simple randomization. The random allocation sequence will be generated using Random Allocation Software. Each eligible participant will be assigned a unique study identification number, and the generated randomization sequence will determine the treatment group. No stratified or block randomization will be used, Blinding description: Participants and treating physicians will not be blinded because of the differences between the treatment regimens. The clinical outcome assessor, ultrasonography assessor, and data analyst will be blinded to treatment allocation. Clinical and ultrasonographic assessments will be performed by independent assessors who are unaware of the participants' treatment assignments. For data analysis, treatment groups will be identified using coded group labels to maintain blinding of the data analyst.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Morphea.</hc_freetext>
      <i_freetext>Intervention 1: Upadacitinib group: Participants allocated to the upadacitinib group will receive oral upadacitinib at a dose of 15 mg once daily for 6 months. If predefined inadequate response is observed during follow-up and there is no contraindication to dose escalation, the dose may be increased to 30 mg once daily. The maximum dose will be 30 mg per day. Treatment will be administered throughout the 6-month study period, with clinical assessments at baseline, month 3, and month 6. Intervention 2: Methotrexate group: Participants allocated to the comparator group will receive oral methotrexate at a dose of 15 mg once weekly for 6 months. If predefined inadequate response is observed during follow-up and there is no contraindication to dose escalation, the dose may be increased to 25 mg once weekly. The maximum dose will be 25 mg per week. Treatment will be administered throughout the 6-month study period, with clinical assessments at baseline, month 3, and month 6.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant data collected during the study, including demographic characteristics, clinical outcome measures, ultrasonographic measurements, treatment allocation, treatment exposure, and safety laboratory data, may be shared upon reasonable request. The shared dataset will not contain directly identifying personal information. Study-related documents, including the study protocol and statistical analysis plan, may also be made available upon reasonable request. Data will not be publicly posted in an identifiable or unrestricted form.

When:
Access to de-identified individual participant data and study-related documents will begin 6 months after publication of the primary study results and will remain available for at least 5 years thereafter, subject to ethical and institutional requirements.

To whom:
Researchers and academic or scientific investigators from universities, research institutions, or other qualified organizations may submit a request for access. Requests from investigators outside academic institutions may also be considered if the proposed use meets the study's ethical and scientific requirements.

Conditions:
Data may be used for scientifically and ethically appropriate research purposes, including secondary analyses, methodological research, and systematic reviews or meta-analyses. Access will be limited to de-identified data and will not permit attempts to re-identify participants. The proposed use must be consistent with the original informed consent and applicable ethical and institutional requirements.

Where to obtain:
Dr. Ifa Etesami

How to obtain:
Applicants should submit a written request describing the purpose of the proposed research, the specific data or documents requested, the proposed analyses, and the intended dissemination of the results. Each request will be reviewed by the principal investigator and the research team for scientific merit, ethical compatibility, participant confidentiality, and compliance with institutional requirements. Additional documentation, such as an institutional affiliation or research ethics approval, may be requested when appropriate. Approved data will be provided in a de-identified format after completion of the required review and any applicable data-use agreement. Requests will normally be reviewed within 4 to 8 weeks of receipt of complete documentation.

Comments:
Data sharing will be subject to applicable ethical, institutional, and legal requirements. The research team reserves the right to decline requests when data sharing could compromise participant confidentiality, conflict with informed consent, or otherwise violate applicable regulations.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ifa Etesami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vahdat-e-eslami street, Razi dermatology hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663911</zip>
        <telephone>+98 21 5561 8989</telephone>
        <email>ifa.etesami@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ifa Etesami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi hospital, Vahdat-eslami square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۱۹۹۶۶۳۹۱۱</zip>
        <telephone>+98 21 5561 8989</telephone>
        <email>ifa.etesami@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>First visit at the Morphea Clinic of Razi Hospital.
No systemic treatment for morphea during the preceding 6 months.
Baseline LoSAI score ≥2.
Diagnosis of plaque or generalized morphea.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Inability or unwillingness to complete study follow-up.
Systemic treatment for morphea during the preceding 6 months.
Linear morphea.
Pregnancy or breastfeeding.
Development of a serious or clinically significant adverse event requiring discontinuation of study treatment.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L94.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Localized scleroderma [morphea]</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Upadacitinib group: Participants allocated to the upadacitinib group will receive oral upadacitinib at a dose of 15 mg once daily for 6 months. If predefined inadequate response is observed during follow-up and there is no contraindication to dose escalation, the dose may be increased to 30 mg once daily. The maximum dose will be 30 mg per day. Treatment will be administered throughout the 6-month study period, with clinical assessments at baseline, month 3, and month 6.</i_keyword>
      <i_keyword>Methotrexate group: Participants allocated to the comparator group will receive oral methotrexate at a dose of 15 mg once weekly for 6 months. If predefined inadequate response is observed during follow-up and there is no contraindication to dose escalation, the dose may be increased to 25 mg once weekly. The maximum dose will be 25 mg per week. Treatment will be administered throughout the 6-month study period, with clinical assessments at baseline, month 3, and month 6.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Localized Scleroderma Cutaneous Assessment Tool (LoSCAT). Timepoint: At baseline before initiation of the intervention, and at month 3 and 6 after initiation of the intervention. Method of measurement: By a trained outcome assessor who is blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Localized Scleroderma Activity Index (LoSAI). Timepoint: At baseline before initiation of the intervention, and at month 3 and 6 after initiation of the intervention. Method of measurement: By a trained outcome assessor who is blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Localized Scleroderma Damage Index (LoSDI). Timepoint: At baseline before initiation of the intervention, and at month 3 and 6 after initiation of the intervention. Method of measurement: By a trained outcome assessor who is blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Physician Global Assessment of Activity. Timepoint: At baseline before initiation of the intervention, and at month 3 and 6 after initiation of the intervention. Method of measurement: By a trained outcome assessor who is blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Physician Global Assessment of Damage. Timepoint: At baseline before initiation of the intervention, and at month 3 and 6 after initiation of the intervention. Method of measurement: By a trained outcome assessor who is blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Dermal thickness. Timepoint: At baseline and month 6 after initiation of the intervention. Method of measurement: Dermal thickness will be measured using soft-tissue ultrasonography and recorded in millimeters by an ultrasonography assessor blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Hypodermal thickness. Timepoint: At baseline and month 6 after initiation of the intervention. Method of measurement: Hypodermal thickness will be measured using soft-tissue ultrasonography and recorded in millimeters by an ultrasonography assessor blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Dermal elasticity. Timepoint: At baseline and month 6 after initiation of the intervention. Method of measurement: Dermal elasticity will be measured using soft-tissue ultrasound elastography and recorded in kilopascals by an ultrasonography assessor blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Hypodermal elasticity. Timepoint: At baseline and month 6 after initiation of the intervention. Method of measurement: Hypodermal elasticity will be measured using soft-tissue ultrasound elastography and recorded in kilopascals by an ultrasonography assessor blinded to treatment allocation.</prim_outcome>
      <prim_outcome>Occurrence of treatment-related adverse events and serious adverse events. Timepoint: Throughout the treatment period and at each follow-up visit through month 6. Method of measurement: Adverse events will be recorded and assessed based on participant reports, clinical examination, routine lab tests, and medical record review throughout follow-up.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-09-19</approval_date>
        <contact_name>Research Ethics Committee, Faculty of Medicine, Tehran University of Medical Sciences</contact_name>
        <contact_address>Vahdate-Eslami street Razi Dermatology Hospital Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
